The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Recombinant Human Endostatin-Global Market Insights and Sales Trends 2025
Synopsis
Endostatin is a naturally occurring, 20-kDa C-terminal fragment derived from type XVIII collagen. Human monomeric endostatin is a globular protein containing two disulfide bonds: Cys162−302 and Cys264−294.
The global Recombinant Human Endostatin market size is expected to reach US$ 238 million by 2029, growing at a CAGR of 8.0% from 2023 to 2029. The market is mainly driven by the significant applications of Recombinant Human Endostatin in various end use industries. The expanding demands from the Medical Care, Scientific Research and Others,, are propelling Recombinant Human Endostatin market. Purity:95%, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Others segment is estimated at % CAGR for the next seven-year period.
The market for recombinant human endostatin is important in cancer treatment. Trends include research into combination therapies and targeted cancer treatments.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Recombinant Human Endostatin, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Recombinant Human Endostatin market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Recombinant Human Endostatin market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Recombinant Human Endostatin sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Recombinant Human Endostatin covered in this report include Thermo Fisher Scientific and PeproTech etc.
The global Recombinant Human Endostatin market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Thermo Fisher Scientific
PeproTech
Global Recombinant Human Endostatin market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Recombinant Human Endostatin market, Segment by Type:
Purity:95%
Others
Global Recombinant Human Endostatin market, by Application
Medical Care
Scientific Research
Others
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Recombinant Human Endostatin manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Recombinant Human Endostatin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Endostatin is a naturally occurring, 20-kDa C-terminal fragment derived from type XVIII collagen. Human monomeric endostatin is a globular protein containing two disulfide bonds: Cys162−302 and Cys264−294.
The global Recombinant Human Endostatin market size is expected to reach US$ 238 million by 2029, growing at a CAGR of 8.0% from 2023 to 2029. The market is mainly driven by the significant applications of Recombinant Human Endostatin in various end use industries. The expanding demands from the Medical Care, Scientific Research and Others,, are propelling Recombinant Human Endostatin market. Purity:95%, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Others segment is estimated at % CAGR for the next seven-year period.
The market for recombinant human endostatin is important in cancer treatment. Trends include research into combination therapies and targeted cancer treatments.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Recombinant Human Endostatin, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Recombinant Human Endostatin market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Recombinant Human Endostatin market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Recombinant Human Endostatin sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Recombinant Human Endostatin covered in this report include Thermo Fisher Scientific and PeproTech etc.
The global Recombinant Human Endostatin market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Thermo Fisher Scientific
PeproTech
Global Recombinant Human Endostatin market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Recombinant Human Endostatin market, Segment by Type:
Purity:95%
Others
Global Recombinant Human Endostatin market, by Application
Medical Care
Scientific Research
Others
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Recombinant Human Endostatin manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Recombinant Human Endostatin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Recombinant Human Endostatin Market Overview
1.1 Recombinant Human Endostatin Product Overview
1.2 Recombinant Human Endostatin Market Segment by Type
1.2.1 Purity:95%
1.2.2 Others
1.3 Global Recombinant Human Endostatin Market Size by Type
1.3.1 Global Recombinant Human Endostatin Market Size Overview by Type (2018-2029)
1.3.2 Global Recombinant Human Endostatin Historic Market Size Review by Type (2018-2023)
1.3.3 Global Recombinant Human Endostatin Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Recombinant Human Endostatin Sales Breakdown by Type (2018-2023)
1.4.2 Europe Recombinant Human Endostatin Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Recombinant Human Endostatin Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Recombinant Human Endostatin Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Recombinant Human Endostatin Sales Breakdown by Type (2018-2023)
2 Global Recombinant Human Endostatin Market Competition by Company
2.1 Global Top Players by Recombinant Human Endostatin Sales (2018-2023)
2.2 Global Top Players by Recombinant Human Endostatin Revenue (2018-2023)
2.3 Global Top Players by Recombinant Human Endostatin Price (2018-2023)
2.4 Global Top Manufacturers Recombinant Human Endostatin Manufacturing Base Distribution, Sales Area, Product Type
2.5 Recombinant Human Endostatin Market Competitive Situation and Trends
2.5.1 Recombinant Human Endostatin Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Recombinant Human Endostatin Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Recombinant Human Endostatin as of 2022)
2.7 Date of Key Manufacturers Enter into Recombinant Human Endostatin Market
2.8 Key Manufacturers Recombinant Human Endostatin Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Recombinant Human Endostatin Status and Outlook by Region
3.1 Global Recombinant Human Endostatin Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Recombinant Human Endostatin Historic Market Size by Region
3.2.1 Global Recombinant Human Endostatin Sales in Volume by Region (2018-2023)
3.2.2 Global Recombinant Human Endostatin Sales in Value by Region (2018-2023)
3.2.3 Global Recombinant Human Endostatin Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Recombinant Human Endostatin Forecasted Market Size by Region
3.3.1 Global Recombinant Human Endostatin Sales in Volume by Region (2024-2029)
3.3.2 Global Recombinant Human Endostatin Sales in Value by Region (2024-2029)
3.3.3 Global Recombinant Human Endostatin Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Recombinant Human Endostatin by Application
4.1 Recombinant Human Endostatin Market Segment by Application
4.1.1 Medical Care
4.1.2 Scientific Research
4.1.3 Others
4.2 Global Recombinant Human Endostatin Market Size by Application
4.2.1 Global Recombinant Human Endostatin Market Size Overview by Application (2018-2029)
4.2.2 Global Recombinant Human Endostatin Historic Market Size Review by Application (2018-2023)
4.2.3 Global Recombinant Human Endostatin Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Recombinant Human Endostatin Sales Breakdown by Application (2018-2023)
4.3.2 Europe Recombinant Human Endostatin Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Recombinant Human Endostatin Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Recombinant Human Endostatin Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Recombinant Human Endostatin Sales Breakdown by Application (2018-2023)
5 North America Recombinant Human Endostatin by Country
5.1 North America Recombinant Human Endostatin Historic Market Size by Country
5.1.1 North America Recombinant Human Endostatin Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Recombinant Human Endostatin Sales in Volume by Country (2018-2023)
5.1.3 North America Recombinant Human Endostatin Sales in Value by Country (2018-2023)
5.2 North America Recombinant Human Endostatin Forecasted Market Size by Country
5.2.1 North America Recombinant Human Endostatin Sales in Volume by Country (2024-2029)
5.2.2 North America Recombinant Human Endostatin Sales in Value by Country (2024-2029)
6 Europe Recombinant Human Endostatin by Country
6.1 Europe Recombinant Human Endostatin Historic Market Size by Country
6.1.1 Europe Recombinant Human Endostatin Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Recombinant Human Endostatin Sales in Volume by Country (2018-2023)
6.1.3 Europe Recombinant Human Endostatin Sales in Value by Country (2018-2023)
6.2 Europe Recombinant Human Endostatin Forecasted Market Size by Country
6.2.1 Europe Recombinant Human Endostatin Sales in Volume by Country (2024-2029)
6.2.2 Europe Recombinant Human Endostatin Sales in Value by Country (2024-2029)
7 Asia-Pacific Recombinant Human Endostatin by Region
7.1 Asia-Pacific Recombinant Human Endostatin Historic Market Size by Region
7.1.1 Asia-Pacific Recombinant Human Endostatin Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Recombinant Human Endostatin Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Recombinant Human Endostatin Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Recombinant Human Endostatin Forecasted Market Size by Region
7.2.1 Asia-Pacific Recombinant Human Endostatin Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Recombinant Human Endostatin Sales in Value by Region (2024-2029)
8 Latin America Recombinant Human Endostatin by Country
8.1 Latin America Recombinant Human Endostatin Historic Market Size by Country
8.1.1 Latin America Recombinant Human Endostatin Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Recombinant Human Endostatin Sales in Volume by Country (2018-2023)
8.1.3 Latin America Recombinant Human Endostatin Sales in Value by Country (2018-2023)
8.2 Latin America Recombinant Human Endostatin Forecasted Market Size by Country
8.2.1 Latin America Recombinant Human Endostatin Sales in Volume by Country (2024-2029)
8.2.2 Latin America Recombinant Human Endostatin Sales in Value by Country (2024-2029)
9 Middle East and Africa Recombinant Human Endostatin by Country
9.1 Middle East and Africa Recombinant Human Endostatin Historic Market Size by Country
9.1.1 Middle East and Africa Recombinant Human Endostatin Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Recombinant Human Endostatin Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Recombinant Human Endostatin Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Recombinant Human Endostatin Forecasted Market Size by Country
9.2.1 Middle East and Africa Recombinant Human Endostatin Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Recombinant Human Endostatin Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Thermo Fisher Scientific
10.1.1 Thermo Fisher Scientific Company Information
10.1.2 Thermo Fisher Scientific Introduction and Business Overview
10.1.3 Thermo Fisher Scientific Recombinant Human Endostatin Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Thermo Fisher Scientific Recombinant Human Endostatin Products Offered
10.1.5 Thermo Fisher Scientific Recent Development
10.2 PeproTech
10.2.1 PeproTech Company Information
10.2.2 PeproTech Introduction and Business Overview
10.2.3 PeproTech Recombinant Human Endostatin Sales, Revenue and Gross Margin (2018-2023)
10.2.4 PeproTech Recombinant Human Endostatin Products Offered
10.2.5 PeproTech Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Recombinant Human Endostatin Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Recombinant Human Endostatin Industrial Chain Analysis
11.4 Recombinant Human Endostatin Market Dynamics
11.4.1 Recombinant Human Endostatin Industry Trends
11.4.2 Recombinant Human Endostatin Market Drivers
11.4.3 Recombinant Human Endostatin Market Challenges
11.4.4 Recombinant Human Endostatin Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Recombinant Human Endostatin Distributors
12.3 Recombinant Human Endostatin Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
